Quince Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QNCX Nasdaq 2836 www.quincetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quince Therapeutics, Inc.

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference - Jun 25th, 2025 2:05 pm
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - Jun 18th, 2025 2:05 pm
June 2025's Promising Penny Stocks For Savvy Investors - Jun 16th, 2025 12:04 pm
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - Jun 12th, 2025 3:15 pm
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Jun 3rd, 2025 2:05 pm
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - May 13th, 2025 6:00 am
Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks - May 4th, 2025 4:46 am
Quince Therapeutics to Present at Citizens Life Sciences Conference - Apr 30th, 2025 2:05 pm
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - Apr 3rd, 2025 2:05 pm
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Mar 24th, 2025 2:05 pm
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Mar 4th, 2025 10:05 am
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Feb 7th, 2025 6:00 am
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 5th, 2025 2:05 pm
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Feb 4th, 2025 2:05 pm
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Jan 28th, 2025 6:00 am
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Jan 27th, 2025 6:00 am
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Jan 23rd, 2025 2:05 pm
Spotlight On US Penny Stocks For January 2025 - Jan 1st, 2025 5:08 pm
Spotlight On US Penny Stocks For November 2024 - Nov 27th, 2024 1:05 pm
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Nov 13th, 2024 2:05 pm